Key result
Continuous infusion doxorubicin demonstrated similar metabolic processing to bolus administration but exhibited greater interpatient variability in serum and urinary anthracycline levels.
Why the study?
What are the pharmacokinetic profiles of short-term and long-term continuous infusion doxorubicin?
Population
15 patients receiving doxorubicin infusion
Design
Case_series
Follow-up
Up to 104 days
Authors
Loading...
PK variability in continuous doxorubicin may support TDM consideration; case data leave optimal regimens open for prospective study.
Observational (n=15)
What are the pharmacokinetic profiles of short-term and long-term continuous infusion doxorubicin?
Continuous infusion doxorubicin shows similar metabolic processing to bolus administration but with greater interpatient variability in pharmacokinetics.
Sweatman et al. (1989) conducted an observational in Cancer (n=15). Continuous infusion doxorubicin vs. Bolus administration (historical comparison) was evaluated on Levels of doxorubicin and metabolites in serum and 24-h timed urine collections. Continuous infusion doxorubicin demonstrated similar metabolic processing to bolus administration but exhibited greater interpatient variability in serum and urinary anthracycline levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: